SecBot SecBot
SECBOTREPLAY Home › Report › MRKR

MRKR · Marker Therapeutics reported financial results for 2025, highlighting a…

Marker Therapeutics · PRESS-RELEASE filed Mar 18, 2026 at 17:31 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 18, 2026 at 17:31 ET

Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower R&D spending, while maintaining a $17 million cash position expected to fund operations into Q4 2026. The company emphasized strong clinical progress, including a 66% objective response rate in lymphoma and promising pancreatic cancer data, with key updates expected in Q2 2026.

  • Net loss widened to $12.2 million in 2025 from $10.7 million in 2024 despite lower R&D expenses ($11.8M vs $13.5M).
  • Cash, cash equivalents, and restricted cash totaled $17.0 million at year-end 2025, down from $19.2 million in 2024.
  • Cash runway expected through Q4 2026 without additional grant funding.
  • MT-601 showed 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with 50% complete responses.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access